Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Evidence quality across them varies considerably
There is only one other FDA-approved treatment for MASH, a drug called Rezdiffra that stimulates thyroid receptors in the liver but does not cause weight loss
These medications can improve heart function, reduce adverse cardiovascular events and even help specific groups, such as patients who have had cardiac bypass surgery, achieve better outcomes
The standard eligibility criteria require either a BMI of 30 or higher, or a BMI of 27 or higher combined with at least one weight-related health condition
16 However, our data demonstrate that long-term administration results in gradual muscle mass loss, ultimately attenuating the initial functional improvements
